Klinikverbund Allgaeu gGmbH — Clinical Trial Site

44 Registered trials

18 Currently recruiting

Organisation

Klinikverbund Allgaeu gGmbH

Location

Kempten (Allgau), Germany

Identifier

ORG-100043973

Address

Robert Weixler Strasse 50, 87439, Germany

Departments

-
2607 : Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin Klinikum Kempten
4508 :MVZ Pneumologie
Abteilung Pneumologie
DE30008:Onkologisches Zentrum
Frauenheilkunde und Geburtshilfe
Gynecology
Gynecology and Obstetrics
Hämatologie / Onkologie
Hämatologie / Onkologie / Palliativmedizin
Hämatologie Onkologie Palliativmedizin
Hämatologie, Onkologie, Palliativmedizin
Hämatologie/Onkologie/Palliativmedizin
Head of department Ob/Gyn
Innere Medizin III - Haematologie und Onkologie
Klinik fuer Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin
Klinik für Frauenheilkunde und Geburtshilfe
Klinik für Pneumologie
Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedi zin
Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedi zin
Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin
Klinik Immenstadt
Klinik Immenstadt, Klinik fuer Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin
Klinikum Kempten
Klinikum Kempten / MVZ Pneumologie im AeH
Klinikum Kempten Hämatologie-Onkologie-Palliativmedizin
Klinikum Kempten, Haematologie / Onkologie
Klinikum Kempten, Hämatolologie/Onkologie
Klinikum Kempten, MVZ Pneumologie im ÄH
Klinikverbund Kempten-Oberallgäu gGmbH, Frauenheilkunde und Geburtshilfe
LUNGENHEILKUNDE / PNEUMOLOGIE
MVZ Klinikum Kempten - Pneumologie, Allergologie, Thoraxonkologie, Bronchoskopie und Schlafmedizin
MVZ Pneumologie
Onkologie
Paediatric clinic
Strahlentherapie Süd
Zentrum für Hämatologische Neoplasien

Clinical trials at this site (44)

Search interface

The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early… Ended

2024-512980-29-00 T1-T2N0 esophageal adenocarcinoma including gastroesoph 4 2023-08-28
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare… Ended

2024-511625-55-00 EGFRmutated/T790M Mutation negative non-squamous NSCLC 6 2022-11-30
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Metastatic or Locally Advanced Epidermal Growth Factor 5 2022-09-01
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Patients with hormone receptor positive HER2 negative l 6 2022-04-26
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended

2024-513433-20-00 Limited Disease Small Cell Lung Cancer 4 2020-12-16
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed … Ended

2022-502658-15-00 Resectable Stage II-IIIB Non-small cell lung cancer 5 2019-09-22
A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended

2023-509576-42-00 Patients with resectable Non-small Cell Lung Cancer (St 5 2019-02-21
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended

2024-515783-31-00 Newly Diagnosed Multiple Myeloma 5 2018-08-24
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Locally advanced or metastatic KRAS G12C-mutated non-sm 4 2022-12-06
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t… Ended

2024-516271-32-00 Adenocarcinoma of the gastroesophageal junction (AEG ty 5 2020-06-03
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Previously Untreated Locally Advanced Non-small Cell Lu 5 2019-11-20
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15